AU2023362056A1 - Antibody-drug conjugate, preparation method and use thereof - Google Patents

Antibody-drug conjugate, preparation method and use thereof Download PDF

Info

Publication number
AU2023362056A1
AU2023362056A1 AU2023362056A AU2023362056A AU2023362056A1 AU 2023362056 A1 AU2023362056 A1 AU 2023362056A1 AU 2023362056 A AU2023362056 A AU 2023362056A AU 2023362056 A AU2023362056 A AU 2023362056A AU 2023362056 A1 AU2023362056 A1 AU 2023362056A1
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
antibody
seq
drug conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023362056A
Other languages
English (en)
Inventor
Shu-Hui Liu
Xun Meng
Jing Shi
Weining WENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Multitude Therapeutics Inc
Original Assignee
Multitude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multitude Therapeutics Inc filed Critical Multitude Therapeutics Inc
Publication of AU2023362056A1 publication Critical patent/AU2023362056A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023362056A 2022-10-19 2023-10-18 Antibody-drug conjugate, preparation method and use thereof Pending AU2023362056A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2022126273 2022-10-19
CNPCT/CN2022/126273 2022-10-19
CNPCT/CN2023/118363 2023-09-12
CN2023118363 2023-09-12
PCT/CN2023/125253 WO2024083161A1 (en) 2022-10-19 2023-10-18 Antibody-drug conjugate, preparation method and use thereof

Publications (1)

Publication Number Publication Date
AU2023362056A1 true AU2023362056A1 (en) 2025-04-24

Family

ID=90737003

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023362056A Pending AU2023362056A1 (en) 2022-10-19 2023-10-18 Antibody-drug conjugate, preparation method and use thereof

Country Status (9)

Country Link
EP (1) EP4605015A1 (https=)
JP (1) JP2025535447A (https=)
KR (1) KR20250080903A (https=)
CN (1) CN120091834A (https=)
AU (1) AU2023362056A1 (https=)
IL (1) IL320035A (https=)
MX (1) MX2025004492A (https=)
TW (1) TW202430221A (https=)
WO (1) WO2024083161A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026037321A1 (en) * 2024-08-13 2026-02-19 Lepu Biopharma Co., Ltd. Compounds, compositions and methods
CN120369658B (zh) * 2025-06-26 2025-08-29 凯莱英生命科学技术(天津)有限公司 测定抗体偶联药物中毒素连接子的消光系数的方法及检测抗体偶联药物中药物抗体偶联比的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7381478B2 (ja) * 2017-10-23 2023-11-15 マブリンク ビオシオンス 単一分子量ポリサルコシンを含むリガンド－薬物－複合体
WO2020132190A1 (en) * 2018-12-21 2020-06-25 Multitude Inc. Antibodies specific to muc18
AU2020216780B2 (en) * 2019-01-28 2025-05-08 Multitude Therapeutics Inc. Antibodies specific to CD44
KR20220024106A (ko) * 2019-05-20 2022-03-03 노파르티스 아게 Mcl-1 억제제 항체-약물 접합체 및 사용 방법
AU2021284401A1 (en) * 2020-06-05 2023-01-05 Eisai R&D Management Co., Ltd. Anti-BCMA antibody-drug conjugates and methods of use

Also Published As

Publication number Publication date
WO2024083161A1 (en) 2024-04-25
EP4605015A1 (en) 2025-08-27
CN120091834A (zh) 2025-06-03
IL320035A (en) 2025-06-01
TW202430221A (zh) 2024-08-01
JP2025535447A (ja) 2025-10-24
MX2025004492A (es) 2025-05-02
KR20250080903A (ko) 2025-06-05

Similar Documents

Publication Publication Date Title
WO2024083161A1 (en) Antibody-drug conjugate, preparation method and use thereof
WO2023102875A1 (en) Anti-cdh6 antibody drug conjugate
US20230277679A1 (en) Method for producing antibody-drug conjugate
CN117693526A (zh) 抗-c-Met抗体药物缀合物
WO2023104188A1 (en) Anti-cdh6 antibodies and antibody-drug conjugates thereof
US12496354B2 (en) CD142 antibodies, antibody-drug conjugates, preparations and uses thereof
WO2024240227A1 (en) Antibodies and antibody-drug conjugates thereof
EP4606822A1 (en) Antibody-drug conjugate, preparation method therefor and use thereof in resisting tumors
EA053275B1 (ru) Конъюгат антитело-лекарственное средство, способ его получения и применение
JP7594708B1 (ja) ネクチン４を標的としエキサテカンペイロードを含む抗体薬物コンジュゲート（ａｄｃ）
WO2024179561A1 (en) Antibody-drug conjugates, pharmaceutical compositions and uses thereof
CA3270684A1 (en) Antibody-drug conjugate, perparation method therefor, and anti-tumor use thereof
EA052998B1 (ru) Конъюгат антитело-лекарственное средство, способ его получения и его противоопухолевое применение
KR20260044235A (ko) 높은 약물 부하를 갖는 항체-약물 접합체 및 그 용도
WO2025206085A1 (ja) 癌の治療及び／又は予防用医薬組成物